NORTHWEST BIOTHERAPEUTICS INC (NWBO)

OTC Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$1.8M
Cash & Equivalents
$12.5M
Quarterly Burn Rate
$293M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06373731 ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With D... PHASE3 Active Not Recruiting 313

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for NWBO.

SEC EDGAR Filings

All SEC filings for NORTHWEST BIOTHERAPEUTICS INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.